Duofuduo: the net profit in the first quarter increased by 650.55% - 682.72% year-on-year

China’s E-bike Brands Going Global: A Review of 26 Leading Players

With the global e-bike market continuing to expand, Chinese e-bike companies are gradually shifting from being a manufacturing powerhouse to becoming a meaningful force in global competition. This article reviews a group of Chinese e-bike players and examines their overseas positioning and market entry paths—looking at how Chinese brands are securing a foothold in the next wave of globalization.

Kanghong’s Conbercept Receives Marketing Authorization in Guyana

Kanghong Pharmaceutical (康弘药业) said its subsidiary Kanghong Bioscience had received a drug registration certificate from Guyana’s Food and Drug Department for conbercept ophthalmic injection, marketed under the brand name Lumitin (朗沐).

ByteDance’s Proposed US$20 Billion Offshore Loan Draws More Than US$30 Billion of Demand

ByteDance (字节跳动) has drawn more than US$30 billion of demand for a proposed syndicated loan that could become its largest offshore borrowing, Bloomberg reported on Aug. 19, underscoring lenders’ appetite to finance the TikTok owner’s expanding artificial-intelligence infrastructure plans.

Unpacking China | Key Chinese Firms to Watch This Week （02/08/2026-08/08/2026）

Amid fast-paced changes that fill the business community with excitement, angst and trepidation, EqualOcean will publish a series of roundup articles to document the major events related to Chinese companies going global every week.

Wantai BioPharm’s Nine-Valent HPV Vaccine Wins First Overseas Approval in Thailand

Wantai BioPharm (万泰生物) announced on Aug. 11 that the nine-valent HPV vaccine developed by its wholly owned subsidiary, Xiamen Innovax Biotech (万泰沧海), has received marketing authorization from Thailand’s Food and Drug Administration. The approval marks the vaccine’s first clearance outside China and an important step in Wantai BioPharm’s international expansion.